Suvisaari, JKeinanen, JEskelinen, SMantere, ODiabetes and schizophrenia. Curr Diabetes Rep 2016; 16:16.
Pedersen, CBMors, OBertelsen, AWaltoft, BLAgerbo, EMcGrath, JJ et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 2014; 71:573–81.
Perälä, JSuvisaari, JSaarni, SIKuoppasalmi, KIsometsä, EPirkola, S et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64:19–28.
Laursen, TMMunk-Olsen, TVestergaard, MLife expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25:83–8.
Leng, CHChou, MHLin, SHYang, YKWang, JDEstimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan. Schizophr Res 2016; 171:97–102.
Hjorthoj, CSturup, AEMcGrath, JJNordentoft, MYears of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4:295–301.
ADA, Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018 [American Dibetes Association]. Diabetes Care 2018; 41:S13–27.
Lin, WHHsu, CHChen, HFLiu, CCLi, CYMortality of patients with type 2 diabetes in Taiwan: a 10-year nationwide follow-up study. Diabetes Res Clin Pract 2015; 107:178–86.
Amos, AFMcCarty, DJZimmet, PThe rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetes Med 14(Suppl. 5)1997; S1–85.
Quan, JLi, TKPang, HChoi, CHSiu, SCTang, SY et al. Diabetes incidence and prevalence in Hong Kong, China during 2006–2014. Diabetes Med 2017; 34:902–8.
Rajkumar, APHorsdal, HTWimberley, TCohen, DMors, OBørglum, AD et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry 2017; 174:686–94.
Maudsley, HThe pathology of mind 1879, Macmillan London.
Andreassen, OADiabetes and schizophrenia-new findings for an old puzzle. Am J Psychiatry 2017; 174:616–7.
Raphael, TParsons, JPBlood sugar studies in dementia praecox and manic-depressive insanity. Arch Neurol Psychiatry 1921; 5:687–709.
Ryan, MCThakore, JHPhysical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71:239–57.
Polimanti, RGelernter, JStein, DJGenetically determined schizophrenia is not associated with impaired glucose homeostasis. Schizophr Res 2018; 195:286–9.
Foley, DLMackinnon, AMorgan, VAWatts, GFCastle, DJWaterreus, A et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry 2016; 50:488–94.
Hansen, TIngason, ADjurovic, SMelle, IFenger, MGustafsson, O et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry 2011; 70:59–63.
Liu, YLi, ZZhang, MDeng, YYi, ZShi, TExploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 2013; 6:S17.
Andreassen, OADjurovic, SThompson, WKSchork, AJKendler, KSO’Donovan, MC et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013; 92:197–209.
Chien, ICHsu, JHLin, CHBih, SHChou, YJChou, PPrevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 2009; 111:17–22.
Hsu, JHChien, ICLin, CHChou, YJChou, PIncidence of diabetes in patients with schizophrenia: a population-based study. Can J Psychiatry 2011; 56:19–26.
Hung, CFWu, CKLin, PYDiabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:523–7.
Stubbs, BVancampfort, DDe Hert, MMitchell, AJThe prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 132:144–57.
Vancampfort, DCorrell, CUGalling, BProbst, MDe Hert, MWard, PB et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 2016; 15:166–74.
Huang, CJLin, CHLee, MHChang, KPChiu, HCPrevalence and incidence of diagnosed depression disorders in patients with diabetes: a national population-based cohort study. Gen Hosp Psychiatry 2012; 34:242–8.
Huang, CJChiu, HCLee, MHWang, SYPrevalence and incidence of anxiety disorders in diabetic patients: a national population-based cohort study. Gen Hosp Psychiatry 2011; 33:8–15.
Huang, CJChiu, HCHsieh, HMYen, JYLee, MHChang, KP et al. Health care utilization and expenditures of persons with diabetes comorbid with anxiety disorder: a national population-based cohort study. Gen Hosp Psychiatry 2015; 37:299–304.
Chien, ICChou, YJLin, CHBih, SHChou, PChang, HJPrevalence and incidence of schizophrenia among National Health Insurance enrollees in Taiwan, 1996–2001. Psychiatry Clin Neurosci 2004; 58:611–8.
Chien, ICChou, YJLin, CHBih, SHChou, PPrevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 2004; 55:691–7.
Stubbs, BVancampfort, DDe Hert, MMitchell, AThe prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015; 132:144–57.
Shafie, SLee, SPOng, SBCWang, PSeow, EOng, HL et al. Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore. Singapore Med J 2018 10.11622/smedj.2018020 [Epub ahead of print].
Sugai, TSuzuki, YYamazaki, MShimoda, KMori, TOzeki, Y et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One 2016; 11:e0166429.
Chang, WCWong, CSMChen, EYHLam, LCWChan, WCNg, RMK et al. Lifetime prevalence and correlates of schizophrenia-spectrum, affective, and other non-affective psychotic disorders in the Chinese adult population. Schizophr Bull 2017; 43:1280–90.
Aschengrau, ASeage, GR IIIEssentials of epidemiology in public health third edition 2014, Jones & Bartlett Learning MA, USA.
Galletly, CAPremature death in schizophrenia: bridging the gap. Lancet Psychiatry 2017; 4:263–5.
Olfson, MGerhard, THuang, CCrystal, SStroup, TSPremature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72:1172–81.
Suetani, SWhiteford, HAMcGrath, JJAn urgent call to address the deadly consequences of serious mental disorders. JAMA Psychiatry 2015; 72:1166–7.
Hoffman, RPThe complex inter-relationship between diabetes and schizophrenia. Curr Diabetes Rev 2017; 13:528–32.
Wilding, JThe importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014; 68:682–91.
Smith, RCJin, HLi, CBark, NShekhar, ADwivedi, S et al. Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 2013; 143:18–24.
Liptzin, BRegier, DAGoldberg, IDUtilization of health and mental health services in a large insured population. Am J Psychiatry 1980; 137:553–8.
Katon, WJRutter, CSimon, GLin, EHLudman, ECiechanowski, P et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005; 28:2668–72.